INSTRUMENT FOR BRAIN CELL IMPLATATION

描述：（申请人摘要）立体定向手术允许在 大脑深处的结构，同时最大限度地减少对组织的损伤， 包围目标建筑传统上，神经外科干预 包括切除病变组织然而，一个新兴的应用程序 神经外科技术的一个重要方面是细胞的植入（神经移植）， 营养因子、基因、化学治疗剂、神经活性化合物或其他 新鲜组织或神经干细胞的神经移植 作为一种重建细胞群的方法， 本地产生的大脑化学物质的水平， 电路 尽管取得了一些成功，但脑细胞注射后的功能恢复仍然存在。 到目前为止是适度的，具有高度的可变性。边缘功能恢复是 与植入细胞的存活率差直接相关。改善 细胞存活将有助于这种潜在的强大的 治疗方法 许多研究已经证明，当细胞存活率增加时， 进样仪器更小，进样量减少。细胞 通过玻璃微量吸管传递的蛋白质含量增加了250% 通过0.5mm不锈钢套管注射的细胞的存活率。 用于人体外科手术的常用注射器的直径为0.5-1 mm。这 本研究拟研制一种脑内微量注射装置， 将少量细胞植入大脑深处， 部位，以最小的侵入性损伤。在第一阶段，我们开发了一个 仪器和演示的概念验证。此设备将扩展到 人类长度，并再次在动物疾病模型中进行测试。我们将执行所有 获得FDA批准作为试验用器械所需的试验， 人类 拟定商业应用： 不可用

DESCRIPTION: (Applicant's abstract) Stereotactic surgery allows procedures on structures deep within the brain, while minimizing damage to tissue above and surrounding the target structure. Traditionally, neurosurgical intervention has involved the removal of pathological tissues. However, an emerging application of neurosurgical technique is the insertion of cells (neurotransplantation), trophic factors, genes, chemo-therapeutics, neuroactive compounds, or other therapeutic agents Neurotransplantation of fresh tissue or neural stem cells holds promise as a method of reconstituting cell populations, supplementing levels of locally produced brain chemicals, and re-establishing neural circuitry. Despite some successes, functional recovery following brain cell injections has to date been modest, with high variability. Marginal functional recovery is directly associated with poor survival of the implanted cells. Improvements in cell survival would contribute to the utility of this potentially powerful therapeutic approach. Numerous studies have demonstrated that cell survival is increased when the injection instrument is smaller and the injection volume is reduced. Cells delivered through a pulled glass micropipette have 250 percent increased survival over cells injected through a 0.5 mm. stainless steel cannula. Commonly used injectors for human surgery are 0.5-1 mm. in diameter. This proposal is to develop an intracerebral microinjection instrument for implanting small volumes of cells deep within the brain, at multiple injection sites, with a minimum of invasive damage. In Phase I, we developed an instrument and demonstrated proof of concept. This device will be scaled to human length, and tested again in animal models of disease. We will perform all testing necessary to obtain FDA approval as an investigational device in humans. PROPOSED COMMERCIAL APPLICATION: Not avaliable